Home » CORGENTECH FILES IND APPLICATION TO BEGIN PHASE I/II TRIAL OF NEW DRUG CANDIDATE FOR ECZEMA
CORGENTECH FILES IND APPLICATION TO BEGIN PHASE I/II TRIAL OF NEW DRUG CANDIDATE FOR ECZEMA
Corgentech has filed an investigational new drug application with the FDA to begin a Phase I/II clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema.
This is the first of two Phase I/II trials to be initiated. The second trial will be conducted in Europe and is expected to be initiated in the first half of 2005 in a similar patient population. The multicenter, randomized, double-blind, dose-ranging trial will evaluate the safety and feasibility of repeated application of three concentrations of NF-kB Decoy in adult patients with mild-to-moderate eczema.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May